BD Partners with Opentrons to Advance Automation in Single-Cell Multiomics Research
- BD collaborates with Opentrons to enhance its Rhapsody® HT Xpress System for single-cell multiomics automation.
- The partnership aims to streamline workflows, accelerating research in oncology and immunology through improved scalability and reproducibility.
- BD's integration of automation reflects a commitment to advancing research methodologies and enhancing productivity in scientific laboratories.
BD and Opentrons Collaborate to Revolutionize Single-Cell Multiomics Automation
Becton, Dickinson and Company (BD), a leader in medical technology, forges a strategic partnership with Opentrons Labworks, Inc. to enhance the capabilities of its single-cell multiomics instruments. This multi-year collaboration focuses on integrating Opentrons’ robotic liquid-handling technology into BD's Rhapsody® HT Xpress System. The initiative aims to streamline complex experimental procedures, thereby accelerating disease research and drug development, particularly in critical fields such as oncology and immunology. The integration is set to provide scientists with enhanced scalability and reproducibility in their studies, addressing the growing demand for efficient workflows in cutting-edge biological research.
The collaboration centers on the automation of essential experimental steps within the BD Rhapsody™ System. By incorporating the Opentrons Flex® platform, the partnership enables hands-free workflows for single-cell multiomics experiments, which are fundamental to understanding cellular behaviors and interactions. Ranga Partha, PhD, Vice President and General Manager of Global Marketing and Strategic Growth Areas at BD Biosciences, emphasizes that this integration will significantly improve the speed at which scientists can derive insights from biological data. The automation-compatible module created for the BD Rhapsody™ System will facilitate next-generation sequencing library preparation and cell capture, thus streamlining processes that are traditionally labor-intensive.
James Atwood, PhD, CEO of Opentrons Labworks, points out the complementary strengths of both companies, which together make advanced single-cell sequencing more accessible and cost-effective for research laboratories. This partnership not only promises to enhance the capabilities of BD's technology but also opens avenues for laboratories involved in both basic and translational research to leverage these advancements. As BD and Opentrons prepare to announce early access opportunities, the scientific community eagerly anticipates the impact this collaboration will have on the future of multiomics research.
In addition to the technological advancements, BD’s collaboration with Opentrons reflects a broader trend in the medical technology industry toward automation and efficiency. As laboratories increasingly seek to enhance productivity and reduce operational costs, partnerships like this one exemplify how strategic alliances can lead to significant innovations in research methodologies. The focus on integrating automation within existing systems underscores a commitment to improving the accessibility of high-quality scientific research tools.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

